GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Cordyceps Sunshine Biotech Holdings Co Ltd (OTCPK:RAJAF) » Definitions » Debt-to-Revenue

RAJAF (Cordyceps Sunshine Biotech Holdings Co) Debt-to-Revenue : 0.54 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cordyceps Sunshine Biotech Holdings Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cordyceps Sunshine Biotech Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.11 Mil. Cordyceps Sunshine Biotech Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.57 Mil. Cordyceps Sunshine Biotech Holdings Co's annualized Revenue for the quarter that ended in Dec. 2023 was $1.26 Mil. Cordyceps Sunshine Biotech Holdings Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.54.

Cordyceps Sunshine Biotech Holdings Co Debt-to-Revenue Historical Data

The historical data trend for Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cordyceps Sunshine Biotech Holdings Co Debt-to-Revenue Chart

Cordyceps Sunshine Biotech Holdings Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A 11.17 0.77

Cordyceps Sunshine Biotech Holdings Co Quarterly Data
Dec20 Dec21 Dec22 Sep23 Dec23
Debt-to-Revenue N/A N/A 2.79 N/A 0.54

Competitive Comparison of Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue

For the Packaged Foods subindustry, Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue falls into.


;
;

Cordyceps Sunshine Biotech Holdings Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.106 + 0.572) / 0.883
=0.77

Cordyceps Sunshine Biotech Holdings Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.106 + 0.572) / 1.264
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Cordyceps Sunshine Biotech Holdings Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cordyceps Sunshine Biotech Holdings Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cordyceps Sunshine Biotech Holdings Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Cordyceps Sunshine Biotech Holdings Co Ltd (OTCPK:RAJAF) » Definitions » Debt-to-Revenue
Comparable Companies
JBSS HLF BRCC USNA HAIN WEST BGS SENEA UTZ CDXC XSWX:NESN XPAR:BN KHC SHSE:603288 GIS K SHSE:600887 SZSE:300999 NSE:NESTLEIND MKC
Traded in Other Exchanges
N/A
Address
Lane 548, Ruiguang Road, 6th Floor, No. 15, Neihu District, Taipei City, TWN
Website
http://www.cordyceps-sunshine.com
Cordyceps Sunshine Biotech Holdings Co Ltd engages in cultivating Chinese rare medicinal herbs, Cattle camphor mushroom raw materials, and selling its finished products. The company has one business segment: cultivating and sales of Chinese rare medicinal herb, taiwanofungus raw material, and its finished products. The company generates revenue from product sales, training, and related parties.

Cordyceps Sunshine Biotech Holdings Co Headlines

No Headlines